J&J Starts The Year With A Bang With 22 Early-Stage Deals
This article was originally published in The Pink Sheet Daily
The new collaborations cross the company’s diversified business, with an emphasis in pharma on drug discovery and early-stage research in collaboration with biotech and academia.
You may also be interested in...
J&J’s new London innovation center has just opened and Boston, San Francisco and Shanghai sites are soon to follow. A J&J executive providing an update in NY faced questions from a somewhat skeptical audience of potential customers, revealing nuances and new information about how the centers will operate.
The dual GLP-1/GIP agonist outpaced Novo's blockbuster GLP-1 analogue at all three doses, including the important low dose, on A1C reduction and weight reduction in patients with type 2 diabetes.
The company released an annual pricing report, showing that Sanofi's US average net prices declined for the fifth year in a row.